The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase

Letrozole is a commonly used treatment option for metastatic hormone receptor-positive (HR+) breast cancer, but many patients ultimately relapse. Due to the importance of phosphoinositide-3 kinase (PI3K) in breast cancer, PI3K inhibitors such as taselisib are attractive for combination with endocrin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoeflich, Klaus P., Guan, Jane, Edgar, Kyle A., O'Brien, Carol, Savage, Heidi, Wilson, Timothy R., Neve, Richard M., Friedman, Lori S., Wallin, Jeffrey J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918946/
https://www.ncbi.nlm.nih.gov/pubmed/27382432
http://dx.doi.org/10.18632/genesandcancer.100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918946/
https://www.ncbi.nlm.nih.gov/pubmed/27382432
http://dx.doi.org/10.18632/genesandcancer.100

Ejemplares similares